Autologous peripheral blood stem cell transplantation (auto-PBSCT) after high dose chemotherapy is usually offered to @entity0 @entity1 carrying a high risk of relapse or having chemosensitive metastatic disease. Whether progression free and overall survival of such @entity1 is improved after auto-PBSCT compared to conventional chemotherapy is a matter of debate. Currently available results of randomised trials could not uniformly prove or disprove auto-PBSCT being advantageous. Yet such studies have not employed any manipulation of the stem cell graft or any post-transplant immunomodulation exploiting the unique immunological environment for @entity5 eradication which exists only after auto-PBSCT. Preliminary data have discussed the ex vivo and in vivo generation of cytotoxic effector cells employing @entity1199 and/or @entity3027 /gamma in the auto-PBSCT setting. Other cytokines such as IL-12, @entity8252 and prolactin have likewise been considered. Several anticancer vaccine protocols after auto-PBSCT are ongoing using monovalent vaccines or anti-idiotypic antibodies. Polyvalent anticancer vaccines, cytokine secreting @entity5 cells, @entity5 pulsed or hybridised dendritic cells (DC) enhanced with cytokines are studied. Monoclonal antibodies (mAb) could assist: unlabelled for pretransplant exvivo purging, post-transplant for enhancing @entity137 ( @entity137 ) or radioimmunoconjugated as an additive cytotoxic part of the conditioning regimen. Autologous graft versus host induction and allogeneic stem cell transplantation (probably with non-myeloablative conditioning followed by donor lymphocyte infusions) are other approaches. Evaluation of successful combinations, optimal dosages and appropriate timing schedules is the subject of future investigations. Since @entity0 @entity1 belong to countless subgroups, a large number of protocols need to be addressed in order to avoid over treatment and prevent relapse.

Blood stem cell transplantation for XXXX : new approaches using pre- peri- post-transplant immunotherapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['ADCC', 'antibody-dependent cell mediated cytotoxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity1199 :: ('3558', 'Gene') :: ['IL-2'] @entity8252 :: ('3600', 'Gene') :: ['IL-15'] @entity3027 :: ('3439', 'Gene') :: ['IFN-alpha']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
